必威体育登录手机SINGAPORE, Singapore -- Agilent Technologies Inc. (NYSE: A) today announced the release of its newProteoAnalyzersystem, in addition to existing product updates at theSingapore Cell and Gene Therapy Pan Asia Summit (SCGT).
必威体育登录手机Agilent's new protein analysis platform, an automated parallel capillary electrophoresis (CE) solution, combines rapid, high-resolution analysis with minimal sample consumption.This allows researchers to examine complex protein mixtures, enabling faster discoveries in pharma, biopharma, and bioengineered food ingredients.
必威体育登录手机Carsten Thomsen, Associate Vice President of APAC Sales for the Diagnostics and Genomics Group at Agilent, said, "We are thrilled to launch the ProteoAnalyzer, which features all the cutting-edge technologies of the biomolecular platform – elevating translational research from compound to novel applications.必威体育登录手机Building on the success of Agilent's CE capabilities, the ProteoAnalyzer prioritizes what researchers value most: enabling breakthrough discoveries that improve the quality of life."
Pharma and biopharma companies increasingly use CE solutions to enhance the development of proteins with potential therapeutic interest.必威体育登录手机To support this, Agilent's ProteoAnalyzer includes easy-to-use QC workflows for assessing the size and purity of proteins such as antibodies and enzymes, and other proteins of interest.
必威体育登录手机In addition to launching the ProteoAnalyzer, Agilent also announced an update to its Flow Cytometer product line at SCGT.The company launched the newNovoCyte Opteonwith solutions designed to revolutionize cell analysis research, boasting up to 5 lasers and 73 detectors.
必威体育登录手机For 25 years, Agilent has been supporting clinical labs to deliver safe and effective answers for real-world health questions worldwide.必威体育登录手机In Asia Pacific, the company partners with research institutes such as Singapore's ACTRIS and South Korea's Theragen Bio, reflecting a strong testament to Agilent's innovative technology advances in supporting the most promising areas of medical research.